Seeking Alpha

Seeking Alpha Portfolio App for iPad

3,279 people get BSX articles and Market Currents by email alert.

Get email alerts on BSX »

BSX

Boston Scientific Corporation

6/19/2013, 9:56 AM ET

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Tuesday, June 18, 8:19 AM Patients with Parkinson's disease showed a 60% mean improvement in motor function after six months in a trial of Boston Scientific's (BSX) Vercise DBS (deep brain stimulation) System. The implant is designed to selectively stimulate targeted areas when inserted in the brain. The study involved 40 subjects. (PR) Comment! [Healthcare]
Monday, June 17, 5:29 PM Boston Scientific (BSX) announces the first implantation of its Vercise DBS System as part of its intrepid clinical trial. The study intends to evaluate the safety and effectiveness of motor function and overall quality of life in patients using the Vercise DBS System for the treatment of Parkinson's disease. Shares -0.3% AH. Comment! [Healthcare]
Friday, May 31, 10:53 AM Wedbush initiates several medical equipment and supply names. Rundown: Boston Scientific (BSX +0.8%), which is "progressing with its turnaround story," is started at Neutral (price target $10) with new product intros serving as "catalysts for higher EPS"; Medtronic (MDT) is started at Neutral (price target $52) and is "an 800-lb. gorilla [facing] growing competition, limited near-term growth, and an overextended valuation"; St. Jude Medical (STJ -0.9%) is started at Outperform (price target $57) as the Durata overhang "is beginning to lose some steam enabling investors to refocus on STJ's healthy pipeline." 1 Comment [Healthcare]
Wednesday, May 22, 2:14 PM Boston Scientific (BSX -1%) slides in spite of reporting positive results earlier today from a pre-specified analysis of the first 60 patients enrolled in its trial evaluating the performance and safety of the Lotus Valve System in symptomatic patients with severe aortic valve disease considered at high risk for surgical valve replacement. The results showed the trials met primary endpoints in both performance and safety. Comment! [Healthcare]
Tuesday, May 21, 11:54 AM Boston Scientific (BSX +0.4%) says five-year data from its Asthma Intervention Research 2 clinical trial presented today demonstrated that the Alair Bronchial Thermoplasty System continues to show benefits in adult patients with severe uncontrolled asthma. The system was shown to provide a sustained reduction in the rate of severe asthma attacks and ER visits over a five year period after treatment. Results were presented at the annual meeting of the American Thoracic Society in Philadelphia Comment! [Healthcare]
Wednesday, May 15, 3:44 PM Boston Scientific (BSX +4.4%) is set to finish strong today after announcing earlier that it's first patient has been enrolled in a clinical investigation evaluating the use of its WallFlex Biliary RX Stent, a self-expanding metal stent used as a bridge to surgery. The study is expected to enroll 294 patients at leading hospitals in Australia, Belgium, Canada, France, Hong Kong, India, Italy and Japan. Comment! [Healthcare, On the Move]
Friday, May 10, 4:33 PM Medtronic (MDT) says data presented at the Heart Rhythm Society's 34th Annual Scientific Sessions show its Lead Integrity Alert software detected pace/sense lead issues in non-MDT leads at a greater rate than standard impedance monitoring alone. The analysis, which focused on BSX's Endotak leads, shows that for every one Endotak pace/sense lead issue detected by impedance monitoring, the LIA software detected four cases that were missed. Comment! [Healthcare]
Thursday, May 9, 2:12 PM Boston Scientific (BSX +5%) hits a new 52-week high after reporting follow-up data from its Protect AF clinical trial demonstrating that its Watchman Left Atrial Appendage Closure device was statistically superior to Bristol-Myers (BMY) Warfarin in preventing cardiovascular death, strokes and systemic embolization. 1 Comment [Healthcare, On the Move]
Friday, April 26, 2:48 PM Boston Scientific (BSX -1.6%) gives back a pre-market pop plus more today, despite being upped to Outperform at Credit Suisse with a price target of $8.75. The firm says the company is on track for the first time in years to post positive sales growth, and that management's "continued commitment to returning to positive sales growth H213 & to improving margins despite a tough pricing environment" is encouraging. Comment! [Healthcare, On the Move]
Thursday, April 25, 10:05 AM More on Boston Scientific (BSX +1.2%) Q1: swings to net loss of $354M from a profit of $113M a year earlier after taking charges of $578M for litigation and restructuring expenses. Sales breakdown: cardiovascular +12%, rhythm management -5%, MedSurg sales +2%. Expects Q2 adjusted EPS of $0.14-0.17 vs consensus of $0.10, and revenue of $1.74-1.8B vs $1.81B; Revises FY guidance: now expects EPS of $0.65-0.70 vs prior outlook of $0.64-0.70 and consensus of $0.41; and revenues of $6.95-7.15B vs $7.05-7.35B prior and expectations of $7.18B. (PR) Comment! [Healthcare, Earnings]
Thursday, April 25, 7:04 AM Boston Scientific (BSX): Q1 EPS of $0.16 beats by $0.07. Revenue of $1.76B (-6% Y/Y) misses by $0.03B. (PR) Comment! [Earnings, Breaking News, Healthcare]
Thursday, April 25, 12:05 AM Notable earnings before Thursday’s open: ABC, AIXG, ALK, ALXN, AME, ASPS, AVT, AZN, BC, BG, BIIB, BLL, BMS, BMY, BSX, BWA, CAB, CAM, CCE, CELG, CFX, CL, CMS, CNX, COP, CRR, CSH, D, DAN, DLX, DNKN, DO, DOW, DST, EQT, ESI, ETR, FAF, GPK, GTI, GTLS, HERO, HOG, HP, HSY, IDCC, IMAX, JBLU, KKR, KMT, LEA, LINE, LKQ, LLL, LUV, LVLT, MDP, MJN, MMM, MO, NBL, NLSN, NMM, NYT, O, ODFL, ORI, OXY, PCS, PDS, PH, PHM, POT, PRLB, PTEN, PVR, RCL, RDWR, RRD, RS, RTN, RYN, SCG, SIAL, SUI, SWK, SWY, TASR, TSRA, TWC, UAL, UPS, UTHR, WBC, XOM, YNDX, ZMH Comment! [Earnings]
Wednesday, April 24, 5:30 PM Notable earnings before Thursday’s open: ABC, AIXG, ALK, ALXN, AME, ASPS, AVT, AZN, BC, BG, BIIB, BLL, BMS, BMY, BSX, BWA, CAB, CAM, CCE, CELG, CFX, CL, CMS, CNX, COP, CRR, CSH, D, DAN, DLX, DNKN, DO, DOW, DST, EQT, ESI, ETR, FAF, GPK, GTI, GTLS, HERO, HOG, HP, HSY, IDCC, IMAX, JBLU, KKR, KMT, LEA, LINE, LKQ, LLL, LUV, LVLT, MDP, MJN, MMM, MO, NBL, NLSN, NMM, NYT, O, ODFL, ORI, OXY, PCS, PDS, PH, PHM, POT, PRLB, PTEN, PVR, RCL, RDWR, RRD, RS, RTN, RYN, SCG, SIAL, SUI, SWK, SWY, TASR, TSRA, TWC, UAL, UPS, UTHR, WBC, XOM, YNDX, ZMH Comment! [Earnings]
Friday, April 12, 3:48 PM Boston Scientific (BSX +0.4%) says it's received FDA approval for its Precision Spectra Spinal Cord Stimulator System. The system, which will be launch on a limited basis in the U.S., uses Illumina 3D software and 32 contacts and is designed to provide improved pain relief to patients who suffer from chronic pain. Comment! [Healthcare]
Thursday, April 11, 4:16 PM Shares of Boston Scientific (BSX -1.5%) tanked into the close of trading today, with no significant news hitting the tape. Comment! [Healthcare, On the Move]
Wednesday, April 3, 2:45 PM Boston Scientific (BSX -2.2%) dips after Credit Suisse analyst Bruce Nudell cut the shares from Outperform to Neutral on valuation earlier today. In his report, Nudell notes that while he doesn't see its current valuation as overstretched, the shares are now within 8% of his target price and with elevated expectations from the Street already priced in, the stock no longer has enough upside to warrant the higher rating. Comment! [Healthcare, On the Move]

1
2
3
4
5
6
...
12
Next Page